Clinical Trial 55283

Philadelphia, PA 19114


Summary:

BHV3000-405: A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention 



Criteria:

✔4-14 migraine attacks per month (moderate or severe intensity)

✔Migraine attacks, on average, lasting 4 - 72 hours if untreated

✔Ability to distinguish migraine attacks from tension/cluster headaches

Drug test will be performed including marijuana


Qualified Participants May Receive:

Total compensation of up to $825

Study-related medication (no placebo)

Exams & lab work at no cost


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.